MU103_10_002e_WL Guidance document Information of PSUR PBRER submission HMV 4

First Page		Document Content
Health Clinical research Pharmaceuticals policy Clinical data management Health informatics Pharmaceutical industry Swissmedic Pharmacovigilance Electronic common technical document Common Technical Document Biosimilar Medication package insert		MU103_10_002e_WL Guidance document Information of PSUR PBRER submission HMV 4 Add to Reading List Source URL: www.swissmedic.ch Download Document from Source Website File Size: 197,54 KB Share Document on Facebook

	CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium DocID: 1vhgc - View Document
	STATE BIOSIMILAR SUBSTITUTION LAWS Please note: This chart is for informational purposes only and does not constitute legal advice or opinions regarding any specific facts relating to the substitution of biosimilars. You DocID: 1t1RV - View Document
	BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi DocID: 1rrNB - View Document
	27 JANUARY 2016 BIOSIMILARS DEVELOPMENT - FROM PRE-CLINIC TO MARKET Several biological products, altogether worth over US$60 billion annual sales, are encountering patent expiry byThis opens up the opportunity for DocID: 1rnQJ - View Document
	January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion ImmunoOncology Deal In yet DocID: 1rlhw - View Document